Genetic Technologies (STU:DU8) Forward Dividend Yield % : 0.00% (As of May. 24, 2024)

View and export this data going back to . Start your Free Trial

What is Genetic Technologies Forward Dividend Yield %?

As of today (2024-05-24), the Forward Annual Dividend Yield of Genetic Technologies is 0.00%.

As of today (2024-05-24), the Trailing Annual Dividend Yield of Genetic Technologies is 0.00%.

STU:DU8's Forward Dividend Yield % is not ranked ^*
in the Medical Diagnostics & Research industry.
Industry Median: 1.67
* Ranked among companies with meaningful Forward Dividend Yield % only.

Genetic Technologies's Dividends per Share for the three months ended in Dec. 2023 was €0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

Competitive Comparison of Genetic Technologies's Forward Dividend Yield %

For the Diagnostics & Research subindustry, Genetic Technologies's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Genetic Technologies's Forward Dividend Yield % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Genetic Technologies's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Genetic Technologies's Forward Dividend Yield % falls into.

Genetic Technologies Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.

Genetic Technologies (STU:DU8) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.

Genetic Technologies Forward Dividend Yield % Related Terms

Thank you for viewing the detailed overview of Genetic Technologies's Forward Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Genetic Technologies (STU:DU8) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Genetic Technologies Ltd (STU:DU8) » Definitions » Forward Dividend Yield %

Comparable Companies

Traded in Other Exchanges

GENE:USA GTG:Australia

Address

60-66 Hanover Street, Fitzroy, Melbourne, VIC, AUS, 3065

Website

https://www.gtglabs.com

Genetic Technologies Ltd is an Australia-based molecular diagnostics company that offers predictive testing and assessment tools to help physicians proactively manage women's health. The company has developed BREVAGenplus which is a clinically validated risk assessment test for non-hereditary breast cancer. It also provides genetic testing services including medical testing, animal testing, forensic testing, and plant testing. The company markets BREVAGenplus to healthcare professionals in breast healthcare and imaging centers, as well as to obstetricians/ gynecologists (OBGYNs) and breast cancer risk assessment specialists. The majority of the company's revenue is generated from Australia and the United States. The group has two operating segments: EasyDNA and GeneType/Corporate.

Genetic Technologies (STU:DU8) Headlines

No Headlines